POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% Drug Patent Profile

Which patents cover Potassium Chloride 0.3% And Sodium Chloride 0.9%, and what generic alternatives are available?

Potassium Chloride 0.3% And Sodium Chloride 0.9% is a drug marketed by Baxter Hlthcare, Fresenius Kabi Usa, and B Braun. and is included in three NDAs.

The generic ingredient in POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% is dextrose; potassium chloride; sodium chloride. There are nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the dextrose; potassium chloride; sodium chloride profile page.

Summary for POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%

US Patents:	0
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%	potassium chloride; sodium chloride	INJECTABLE;INJECTION	017648-002	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
B Braun	POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	dextrose; potassium chloride; sodium chloride	INJECTABLE;INJECTION	019630-030	Feb 17, 1988	AP	RX	No	No
Fresenius Kabi Usa	POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%	potassium chloride; sodium chloride	INJECTABLE;INJECTION	212347-002	Sep 17, 2020	AP	RX	No	No
B Braun	POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	dextrose; potassium chloride; sodium chloride	INJECTABLE;INJECTION	019630-048	Feb 17, 1988		RX	No	No

Investment Scenario and Fundamentals Analysis for Potassium Chloride 0.3% and Sodium Chloride 0.9%

Last updated: February 3, 2026

Market Overview and Demand Drivers

Potassium chloride (KCl) 0.3% and sodium chloride (NaCl) 0.9% are isotonic solutions used primarily in intravenous therapy to restore fluid and electrolyte balance. The global infusion therapy market was valued at approximately $18 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6% over the next five years, driven by aging populations, increasing incidences of dehydration, and the rising prevalence of chronic diseases requiring IV therapy [1].

The core demand stems from hospitals, clinics, and emergency settings. The COVID-19 pandemic expanded the use of IV solutions, emphasizing their importance. Growth prospects include increased adoption in emerging markets where healthcare infrastructure improves and population health outcomes target electrolyte replacement therapies.

Market Segmentation and Sales Dynamics

• Geographical regions:

  • North America accounts for 40% of demand, driven by high healthcare spending and established hospital infrastructure.
  • Europe holds about 25%, with steady growth.
  • Asia-Pacific registers the fastest growth, projected at 8% CAGR, owing to rapid industrialization, urbanization, and healthcare investment.
  • Latin America and Africa collectively represent around 10%, with growth possibility in volume driven by expanding healthcare infrastructure.

• End-use sectors:

  • Hospitals (acute care, surgical units): 70%
  • Long-term care and clinics: 20%
  • Emergency services: 10%

The product's label indications encompass electrolyte balance correction, dehydration management, and certain chronic condition treatments. The stability, straightforward manufacturing process, and low cost of these solutions support widespread use.

Supply Chain and Production Fundamentals

• Raw materials: Potassium chloride and sodium chloride are mined as mineral salts or produced via chemical synthesis. Both formulations require pharmaceutical-grade purity standards.

• Manufacturing:

  • Large-scale chemical synthesis or mineral extraction.
  • Sterilization processes, predominantly via autoclaving or filtration.
  • Aseptic filling into IV bags or bottles under strict GMP guidelines.

• Quality control:

  • Tests for endotoxins, sterility, pH, and particulate matter.
  • Compliance with pharmacopeial standards (USP, EP, JP).

Manufacturers with established GMP facilities and strong quality assurance protocols tend to dominate global supply. Margins for raw materials tend to be stable but are sensitive to fluctuations in mineral prices and supply disruptions.

Regulatory and Patent Landscape

While the active ingredients are off-patent, manufacturing processes, packaging, and delivery systems can be protected by patents and regulatory exclusivities. Regulatory approval processes involve submission of manufacturing data, stability profiles, and clinical validation of the sterile product.

The global regulatory landscape is complex:

• The US FDA classifies these solutions as sterile drug products.
• European agencies follow the European Pharmacopoeia standards.
• Emerging markets develop local regulatory pathways that are becoming more aligned with international standards.

No recent patent conflicts exist for the basic formulations, but derivative delivery systems or enhanced stability formulations may carry patent protections.

Competitive Landscape

The market includes key players:

• Baxter International
• B. Braun Melsungen AG
• Fresenius Kabi
• Pfizer
• Hikma Pharmaceuticals

Market share varies with geographic regions and specific formulations. Generic manufacturers hold approximately 60% market share globally. Profitability is influenced by manufacturing scale, quality standards, and regulatory compliance.

Pricing Trends and Market Dynamics

Wholesale prices for large-volume IV solutions are relatively stable, with slight downward pressure from generic competition. Pricing varies by region; North America features higher prices ($0.50–$1.00 per unit), while emerging markets commonly see lower costs ($0.10–$0.50 per unit).

Reimbursement policies and procurement contracts significantly influence profitability. Price margins depend on manufacturing efficiency, supply chain logistics, and regional market regulations.

Investment Considerations

• Growth opportunities: Expansion driven by market penetration in developing economies and innovations in stability or delivery systems.

• Risks:

  • Regulatory hurdles may delay market entry.
  • Price competition from generics exerts downward pressure.
  • Supply chain disruptions for raw materials could impact production costs.

• Entry barriers:

  • Stringent quality standards.
  • High capital investment for GMP manufacturing facilities.
  • Regulatory approval lead times.

• Partnership potential:

  • Licensing agreements with established manufacturers.
  • Contract manufacturing to access emerging markets.

Financial Outlook and Valuation Metrics

• Typical gross margins for sterile injectable solutions range from 20% to 40%, depending on scale and market access.
• Market entry costs are substantial, often exceeding $50 million for certified manufacturing capacity.
• Volumes and pricing stability suggest moderate revenue predictability, with annual revenues potentially reaching hundreds of millions for well-positioned players.

Key Takeaways

• The global electrolyte solution market is stable with predictable demand, driven by routine healthcare needs.
• Manufacturing involves low-to-moderate technological complexity, with high regulatory barriers.
• Growth is concentrated in emerging markets, but competition remains intense in mature regions.
• Profitability depends on manufacturing scale, regulatory compliance, and effective supply chain management.
• Investment prospects are favorable for companies with established GMP operations, supply chain resilience, and regional market access.

FAQs

1. What are the main growth drivers for electrolyte solutions like potassium and sodium chloride?
The primary drivers are increasing healthcare infrastructure, aging populations, chronic disease prevalence, and expanding use in emerging markets. Demand surged during the COVID-19 pandemic due to increased hospitalization and IV therapy needs.

2. How do regulatory differences impact market entry?
Regulatory processes differ geographically; the US FDA requires extensive clinical data and GMP compliance, while markets like China and India develop their approval pathways, which may be less rigorous but still demanding. Inefficiencies can delay product launches.

3. What are the key factors affecting profit margins in this market?
Margins depend on manufacturing scale, raw material costs, regulatory compliance costs, and regional pricing. Large-scale production yields lower unit costs, while strict quality standards add to expenses.

4. How susceptible is this market to price competition?
High competition among generic manufacturers exerts downward pressure on prices. Brand differentiation relies on quality assurance, supply reliability, and cost leadership.

5. What potential innovations could influence future investment prospects?
Advancements include improved stability formulations, integrated delivery systems, and digital tracking of supply chains. These innovations can differentiate products and access new market segments.

---

Sources

[1] MarketsandMarkets. Clinical Trial Market Outlook. 2022.